New hope for sickle cell patients blocked from transplants
NCT ID NCT06358638
First seen Nov 01, 2025 · Last updated Apr 09, 2026 · Updated 21 times
Summary
This study is testing if adding a drug called daratumumab before a bone marrow transplant from a matched sibling can safely help children and young adults with severe sickle cell disease who are usually excluded from this treatment. These patients are excluded because their immune system has antibodies that attack the donor's red blood cells, which can cause serious complications. The goal is to see if this approach allows successful transplants with outcomes similar to patients without these antibodies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.